EUVIMEDOpdag EUVIMED
Klinische Studie (Phase I)Open access · CC BY-NC 4.0

Evaluation of Drug–Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Healthy Participants

Alison Luckey iD, Kajal B Larson, Noha Rayad iD, Markus Heep, Sophie Delhomme, Gabrielle Kornmann iD, John P Mueller iD, John P O'Donnell iD, Seamus O'Brien iD, Rainard Fuhr, Jean-Yves Gillon iD

Clinical and Translational Science · 2026-03 · 19 (3)

DOI: 10.1111/cts.70515 ↗

At a glance

Klinische Studie (Phase I) in Clinical and Translational Science, published online on 2026-02-27. Written by Alison Luckey and 10 co-authors. Institution: Global Antibiotic Research & Development Partnership (GARDP), Geneva, Switzerland. Major MEDLINE topics: Anti-Bacterial Agents, Biphenyl Compounds, Cytochrome P-450 CYP3A Inhibitors, Itraconazole. Cited 2 times so far (Crossref); 31 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Zoliflodacin is a first‐in‐class oral spiropyrimidinetrione antibiotic being developed for patients with uncomplicated gonorrhea, including those infected with multidrug‐resistant strains. Because zoliflodacin is metabolized by cytochrome P450 3A4 (CYP3A4), concomitant administration with a CYP3A inhibitor has the potential to increase zoliflodacin plasma exposure. The aim of this phase 1 drug–drug interaction (DDI) study was to assess the effect of the strong CYP3A4 inhibitor itraconazole on the pharmacokinetics (PK) and safety of a 3 g single oral dose of zoliflodacin. This was an open label, 2‐period, 2‐treatment, fixed sequence crossover DDI study. Eighteen eligible adult participants were dosed and completed the study. When zoliflodacin was co‐administered with itraconazole at steady state, as determined by itraconazole trough plasma concentrations, zoliflodacin exposure increased as measured by peak concentration (C max ) by 1.03‐fold and by area under the plasma‐concentration time curve (AUC) from time 0 to last measurable plasma concentration (AUC 0‐last ) and from time 0 extrapolated to infinity (AUC 0‐∞ ) by 1.39‐ and 1.38‐fold, respectively. Eight participants (44.4%) had a total of 15 mild treatment‐emergent adverse events (TEAEs), with three considered related to treatment. There were no deaths or serious TEAEs and no participant withdrew. No clinically significant abnormal laboratory values, vital signs, or electrocardiogram findings were reported. In conclusion, the C max of zoliflodacin was essentially unchanged (1.03‐fold higher) when co‐administered with a strong CYP3A4 inhibitor, while AUC exposures increased by less than 1.5‐fold, which, combined with an acceptable safety profile, indicate a low DDI potential between zoliflodacin and CYP3A4 inhibitors.

Subjects

MeSH terms (MEDLINE)

Anti-Bacterial AgentsBiphenyl CompoundsCytochrome P-450 CYP3A InhibitorsItraconazoleAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultAdministration, OralArea Under CurveCross-Over StudiesCytochrome P-450 CYP3ADrug InteractionsHealthy VolunteersBarbituratesIsoxazolesSpiro CompoundsOxazolidinonesMorpholines

Author keywords

antibioticsdrug–drug interactionsmetabolismpharmacokineticssafety

Substances

Anti-Bacterial AgentsBiphenyl CompoundsCYP3A4 protein, humanCytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsItraconazolezoliflodacinBarbituratesIsoxazolesSpiro Compounds

Authors and institutions

  • Global Antibiotic Research & Development Partnership (GARDP), Geneva, Switzerland.
  • Innoviva Specialty Therapeutics, Inc., Waltham, Massachusetts, USA.
  • Parexel International (MA) Corporation, Mississauga, Ontario, Canada.
  • Drugs for Neglected Diseases Initiative (DNDi), Geneva, Switzerland.
  • Parexel International GmbH, Berlin, Germany.

ORCID profiles: Alison Luckey, Noha Rayad, Gabrielle Kornmann, John P Mueller, John P O'Donnell, Seamus O'Brien, Jean-Yves Gillon

Cite

APA

Luckey, A., Larson, K. B., Rayad, N., Heep, M., Delhomme, S., Kornmann, G., Mueller, J. P., O'Donnell, J. P., O'Brien, S., Fuhr, R., & Gillon, J. Y. (2026). Evaluation of Drug–Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Healthy Participants. Clinical and Translational Science, 19(3). https://doi.org/10.1111/cts.70515

Vancouver

Luckey A, Larson KB, Rayad N, Heep M, Delhomme S, Kornmann G, et al. Evaluation of Drug–Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Healthy Participants. Clinical and Translational Science. 2026;19(3). doi:10.1111/cts.70515

BibTeX
@article{Luckey2026,
  author = {Luckey, Alison and Larson, Kajal B and Rayad, Noha and Heep, Markus and Delhomme, Sophie and Kornmann, Gabrielle and Mueller, John P and O'Donnell, John P and O'Brien, Seamus and Fuhr, Rainard and Gillon, Jean-Yves},
  title = {Evaluation of Drug–Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Healthy Participants},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {3},
  doi = {10.1111/cts.70515}
}
Start for free →